Evidence map›Paper›PMID 42489345›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

A Second Pathogenic Protein, PolyGN2C-iso2, Reveals a Dual-Protein Pathology in Neuronal Intranuclear Inclusion Disease.

Kang Zhang, Wenhao Ma, Yi Zhou, Zhijie Wu, Pan Gao, Hongze Niu, Hongfei Tai, Tianyi Zhao, Zheyue Dong, Li Li and 13 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Kang ZhangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Wenhao MaGeneCradle Therapeutics lnc., Beijing, China.
Yi ZhouDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Zhijie WuGeneCradle Therapeutics lnc., Beijing, China.
Pan GaoGeneCradle Therapeutics lnc., Beijing, China.
Hongze NiuGeneCradle Therapeutics lnc., Beijing, China.
Hongfei TaiDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-4335-9270
Tianyi ZhaoGeneCradle Therapeutics lnc., Beijing, China.
Zheyue DongGeneCradle Therapeutics lnc., Beijing, China.
Li LiGeneCradle Therapeutics lnc., Beijing, China.
Yan ZhangGeneCradle Therapeutics lnc., Beijing, China.
An WangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Si ShenDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yueyang LiBeijing Institute for Brain Research, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Sifei YuBeijing Institute for Brain Research, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Yan PengBeijing Institute for Brain Research, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Wang ShengBeijing University of Technology, Beijing, China.ORCID https://orcid.org/0000-0003-4042-5102
Xiaoyan DongGeneCradle Therapeutics lnc., Beijing, China.
Hua PanDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-0869-8875
Kaibin ShiDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Magdalena J KoziolBeijing Institute for Brain Research, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Xiaobing WuGeneCradle Therapeutics lnc., Beijing, China.
Zaiqiang ZhangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-0053-3451

Funding

Beijing Talent Program, co-funded by Beijing Tiantan Hospital and the Chinese Institute for Brain Research, BeijingBeijing Yicheng Cooperation Development Public Welfare Fund YCXJ-JZ-2023-017Beijing Yicheng Cooperation Development Public Welfare Fund YJXJ-JZ-2021-0014Chinese Institute for Brain Research, Beijing core grant and Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences 2019-I2M-5-015National Natural Science Foundation of China 82271903National Natural Science Foundation of China 88201562
6 · The paper itself

Abstract

backgroundNeuronal intranuclear inclusion disease (NIID) pathogenesis has been strongly linked to uN2CpolyG translated from NOTCH2NLC transcript variant 1. However, emerging evidence suggests that NOTCH2NLC transcript variant 2 may also generate a disease-relevant protein, PolyGN2C-iso2, but isoform-discriminating and antibody-independent evidence remains incomplete.

methodsWe characterize the aggregation propensity of PolyGN2C-iso2 in vitro, develop isoform-discriminating monoclonal antibodies for its detection in patient tissues, and perform targeted proteomic analysis of laser-microdissected p62-positive lesion cells. An AAV-mediated mouse model expressing PolyG(108×)N2C-iso2 is generated to assess its pathogenic potential, followed by behavioral, imaging, histopathological, proteomic, and functional analyses.

resultsNOTCH2NLC transcript variant 2 generates a distinct protein, PolyGN2C-iso2, which forms aggregates in vitro. Using developed monoclonal antibodies together with targeted proteomics, we provide evidence that PolyGN2C-iso2 is present within the pathognomonic intranuclear inclusions in NIID patient tissues, where it co-localizes with uN2CpolyG. The PolyG(108×)N2C-iso2 mouse model recapitulates key pathological hallmarks of NIID, including white matter abnormalities and cognitive deficits not fully captured by previous models. Mechanistically, PolyGN2C-iso2 expression is found to induce profound mitochondrial dysfunction.

conclusionsOur findings support the possibility that NIID involves a dual-protein pathogenic process involving both uN2CpolyG and PolyGN2C-iso2, which may have implications for therapeutic strategies targeting NOTCH2NLC-derived pathogenic proteins.

Indexed as

dual‐proteinopathyGGC repeat expansionmitochondrial dysfunctionneuronal intranuclear inclusion diseaseNOTCH2NLCPolyGN2C‐iso2

Identifiers

PMID42489345
PMCPMC13393261

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.